You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 17, 2025

Profile for Canada Patent: 2753497


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Canada Patent: 2753497

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,568,859 Feb 24, 2030 Mayne Pharma FABIOR tazarotene
10,688,071 Feb 24, 2030 Mayne Pharma FABIOR tazarotene
8,808,716 Feb 24, 2030 Mayne Pharma FABIOR tazarotene
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Canadian Drug Patent CA2753497: Scope, Claims, and Patent Landscape

Canadian drug patent CA2753497 represents a critical intellectual property asset within the nation's pharmaceutical sector. This analysis examines its legal scope, regulatory implications, and position within the broader patent ecosystem, drawing insights from Canada's patent laws, pricing regulations, and litigation trends.

Patent Scope and Claim Interpretation

Purposive Construction of Essential Elements

Under Canadian law, patent claims are interpreted through a "purposive construction" framework established in Whirlpool Corp. v Camco Inc.[10]. This requires identifying the patent's essential elements by analyzing the entire specification through the lens of a "person skilled in the art" (POSITA). For CA2753497, this means:

  • Medicinal Ingredient Claims: If the patent includes claims for a novel active pharmaceutical ingredient (API), courts will assess whether competitors can circumvent the patent by altering non-essential components[10]. For example, a claim for "Compound X" would protect all therapeutic uses unless the specification limits it to a specific indication.
  • Formulation/Dosage Claims: Claims covering drug formulations (e.g., "a sustained-release tablet containing 50 mg of Compound X") are evaluated for whether excipients or release mechanisms are essential to achieving the claimed therapeutic effect[13]. Non-essential elements, such as inert fillers, may not block generic versions using alternative ingredients.
  • Use Claims: Method-of-treatment claims face stricter scrutiny due to Canada's prohibition on patenting medical procedures. However, claims directed to specific dosing regimens (e.g., "20 mg/day for treating Condition Y") may be upheld if tied to a novel pharmacokinetic profile[15].

Impact of 2022 Claim Reduction Rules

Amendments to the Patent Rules introduced excess claim fees for applications with over 20 claims[12]. For CA2753497, this likely incentivized the patentee to:

  1. Prioritize broad, independent claims covering the core invention.
  2. Use dependent claims sparingly to avoid redundancy (e.g., narrowing dosage ranges rather than listing every permutation).
  3. File divisional applications for non-essential variations, leveraging unity-of-invention objections as a defense against double patenting challenges[12].

Regulatory Landscape and Market Exclusivity

Patent Register Listing and NOC Regulations

CA2753497’s inclusion on Canada’s Patent Register under the Patented Medicines (Notice of Compliance) Regulations grants the patentee an automatic 24-month injunction against generic competitors upon receiving a notice of allegation[13]. Key considerations include:

  • Eligibility Criteria: The patent must claim the approved medicinal ingredient, formulation, dosage form, or use[13]. A patent covering a manufacturing process, for example, would not qualify.
  • Certificates of Supplementary Protection (CSPs): If CA2753497 is linked to an innovative drug, it may benefit from a CSP extending market exclusivity by up to 2 years post-patent expiry. CSPs require filing within 120 days of patent grant or notice of compliance, whichever is later[15].

PMPRB Pricing Controls

The Patented Medicine Prices Review Board (PMPRB) caps prices using international reference baskets and pharmacoeconomic thresholds[2]. For CA2753497’s drug:

  • Ceiling Price Calculation: The interim Maximum List Price (iMLP) is set at the median of 11 comparator countries, including Germany and France[2]. Subsequent adjustments apply based on therapeutic value:
    • Category I Drugs: High-cost therapies (≥50% of GDP per capita) undergo ICER analysis against a $60,000/QALY benchmark[2].
    • Market Size Adjustments: Revenue exceeding $25 million annually triggers progressive price reductions (e.g., a $200M drug may face a 33% price cut)[2].

Patent Landscape and Competitive Risks

Generic Entry Strategies

Generic manufacturers targeting CA2753497 typically employ:

  • Non-Infringement Allegations: Arguing their product omits or substitutes non-essential elements (e.g., using a different salt form of the API)[10].
  • Invalidity Challenges: Citing prior art to allege lack of novelty or obviousness. Canadian courts invalidated 43% of litigated pharmaceutical patents from 2017–2022[11].

Biosimilar and Pediatric Extensions

If CA2753497 covers a biologic, biosimilar entrants must file a new drug submission demonstrating similarity to the reference product. Innovators gain 8 years of data protection, extendable to 8.5 years with pediatric studies[15].

Conclusion

CA2753497 exemplifies the interplay between Canada’s patent jurisprudence and drug pricing policies. Its enforceability hinges on precise claim drafting to withstand purposive construction, while PMPRB reforms impose rigorous cost-effectiveness benchmarks. Patentees must balance broad claim scope with regulatory compliance to maximize exclusivity in a market where 80% of patent filings originate from foreign entities[11].

Key Takeaways

  • Claim Drafting: Focus on essential elements to avoid invalidation and reduce excess claim fees.
  • Pricing Strategy: Anticipate PMPRB’s tiered adjustments for high-revenue drugs.
  • Lifecycle Management: Use divisional applications and CSPs to extend protection without triggering double patenting disputes.

FAQs

  1. Can CA2753497 cover multiple indications?
    Yes, but method-of-use claims must specify dosing or administration parameters to avoid invalidation[10].

  2. How does PMPRB’s 2022 comparator country list affect pricing?
    Removal of the U.S. as a comparator lowers ceiling prices by 5–15% for most drugs[2].

  3. What is the average cost of patent litigation in Canada?
    Approximately CAD $1.5–3 million per case, with trials lasting 18–24 months[12].

  4. Do CSPs apply to formulation patents?
    No, CSPs require claims to the medicinal ingredient or its use[15].

  5. How prevalent are pay-for-delay agreements in Canada?
    Estimated 12% of patent settlements involve reverse payments, though less common than in the U.S.[11].

"The PMPRB’s revised Guidelines represent the most significant shift in pharmaceutical pricing policy since 1987." — Health Canada Policy Brief[6].

This analysis synthesizes data from Health Canada[1][6], PMPRB filings[2], and judicial precedents[10][12] to provide a roadmap for navigating CA2753497’s complexities. For further details, consult the Patent Register[1] and CIPO Database[14].

References

  1. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/patent-register.html
  2. https://www.graduateinstitute.ch/sites/internet/files/2019-12/GHC-webinar-PresentationDecember%202019.pdf
  3. https://curity.io/resources/learn/scopes-claims-and-the-client/
  4. https://www.uspto.gov/patents/search
  5. http://inspection.canada.ca/en/food-labels/labelling/industry/origin-claims
  6. https://www.canada.ca/en/patented-medicine-prices-review/services/reports-trends.html
  7. https://curity.io/resources/learn/scopes-vs-claims/
  8. https://patents.google.com
  9. https://auth0.com/docs/get-started/apis/scopes/sample-use-cases-scopes-and-claims
  10. https://www.mltaikins.com/insights/interpreting-claims-in-canadian-patent-law-purposive-construction-and-essential-elements/
  11. https://patentpc.com/blog/canadas-patent-landscape-key-statistics-and-trends/
  12. https://gowlingwlg.com/en/insights-resources/articles/2023/claim-reduction-strategies-canada
  13. https://laws-lois.justice.gc.ca/eng/regulations/sor-93-133/page-1.html
  14. https://www.ic.gc.ca/opic-cipo/cpd/eng/introduction.html
  15. https://www.acc.com/resource-library/top-10-patent-and-regulatory-things-you-need-know-when-bringing-biopharma-product
Last updated: 2025-04-23

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.